stockportfolio.pro
Integra LifeSciences Holdings Corporation (IART)
Healthcare · Medical Devices · NasdaqGS
Integra LifeSciences Holdings Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $992.08M | $1.19B | $1.47B | $1.52B | $1.37B | $1.54B | $1.56B | $1.54B | $1.61B | $1.64B |
| Gross profit | $642.99M | $752.73M | $900.95M | $952.88M | $851.03M | $944.64M | $970.31M | $884.74M | $882.06M | $831.62M |
| Net income | $74.56M | $64.74M | $60.80M | $50.20M | $133.89M | $169.07M | $180.55M | $67.74M | $-6.94M | $-516.47M |
| Net margin | 7.5% | 5.4% | 4.1% | 3.3% | 9.8% | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% |
Source: Integra LifeSciences Holdings Corporation SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of Integra LifeSciences Holdings Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IART in your portfolio →
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Integra LifeSciences Holdings Corporation — frequently asked questions
What is Integra LifeSciences Holdings Corporation's revenue?
Integra LifeSciences Holdings Corporation (IART) reported revenue of $1.64B for fiscal year 2025, up 1.5% from the prior year, according to its SEC filings.
Is Integra LifeSciences Holdings Corporation profitable?
No — IART reported a net loss of $-516.47M in fiscal 2025.
What is IART's P/E ratio?
Integra LifeSciences Holdings Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Integra LifeSciences Holdings Corporation growing?
IART's revenue grew at roughly 3.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Integra LifeSciences Holdings Corporation's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.